Abstract
The COVID-19 (here specifically called Worldwide Acute Respiratory Syndrome, WARS) pandemic is surging worldwide. Unfortunately, no specific drug meets the urgent need to fight this pandemic, leading to thousands of deaths. The theory of host-directed therapies (HDTs) is viewed as the ideal means to rephrase the treatment of infectious diseases. However, related drugs based on this theory have not been identified. Previously, we realized that caffeine is the ligand of type 2 taste receptors (TAS2Rs), which play a critical role in host defense. Here, we gathered data on caffeine acting as an immunomodulator. Unexpectedly, we found that caffeine can fight WARS by acting on multiple organs, which may prevent the virus from entering the cell, stimulate the phagocytosis of macrophages, enhance breathing, and inhibit the cytokine storm. Thus, the immunoprotective effects of caffeine can improve the therapeutic outcomes in patients infected with coronavirus. Collectively, we report that caffeine, an FDA-approved, highly safe, inexpensive, and widely available drug, could be an excellent HDT for battling WARS.
Keywords: COVID-19, 2019-nCoV, SARS-CoV-2, WARS, WARS-CoV, caffeine, cytokine storm, immunomodulator, drug, TAS2R.
Current Medicinal Chemistry
Title:Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS
Volume: 28 Issue: 27
Author(s): Lianyong Liu, Chaobao Zhang, Juan Chen and Xiangqi Li*
Affiliation:
- Department of Endocrinology, Shanghai Gongli Hospital, The Second Military Medical University, Shanghai 200135,China
Keywords: COVID-19, 2019-nCoV, SARS-CoV-2, WARS, WARS-CoV, caffeine, cytokine storm, immunomodulator, drug, TAS2R.
Abstract: The COVID-19 (here specifically called Worldwide Acute Respiratory Syndrome, WARS) pandemic is surging worldwide. Unfortunately, no specific drug meets the urgent need to fight this pandemic, leading to thousands of deaths. The theory of host-directed therapies (HDTs) is viewed as the ideal means to rephrase the treatment of infectious diseases. However, related drugs based on this theory have not been identified. Previously, we realized that caffeine is the ligand of type 2 taste receptors (TAS2Rs), which play a critical role in host defense. Here, we gathered data on caffeine acting as an immunomodulator. Unexpectedly, we found that caffeine can fight WARS by acting on multiple organs, which may prevent the virus from entering the cell, stimulate the phagocytosis of macrophages, enhance breathing, and inhibit the cytokine storm. Thus, the immunoprotective effects of caffeine can improve the therapeutic outcomes in patients infected with coronavirus. Collectively, we report that caffeine, an FDA-approved, highly safe, inexpensive, and widely available drug, could be an excellent HDT for battling WARS.
Export Options
About this article
Cite this article as:
Liu Lianyong , Zhang Chaobao , Chen Juan and Li Xiangqi *, Rediscovery of Caffeine: An Excellent Drug for Improving Patient Outcomes while Fighting WARS, Current Medicinal Chemistry 2021; 28 (27) . https://dx.doi.org/10.2174/0929867327666201103162810
DOI https://dx.doi.org/10.2174/0929867327666201103162810 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies
Current Cancer Drug Targets Protective Effects of Phenylpropanoids and Phenylpropanoid-rich Essential Oils on the Cardiovascular System
Mini-Reviews in Medicinal Chemistry Synthesis, Physico-Chemical Properties and DFT Calculations of New 2-(4- Arylpiperazine-1-yl)-1-(3-ethylbenzofuran-2-yl)ethanols As Potential Antihypertensive Agents
Current Organic Chemistry Neuroleptics and Migraine
Central Nervous System Agents in Medicinal Chemistry Management of Hypertension in Patients with Aortic Valvular Stenosis
Current Hypertension Reviews Active Metabolites Resulting from Decarboxylation, Reduction and Ester Hydrolysis of Parent Drugs
Current Drug Metabolism Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Need for Nutritious Convenience Foods for the Elderly Population: A Review
Current Nutrition & Food Science Editorial
Current Pediatric Reviews An Efficient and Environmentally Benign Access Towards Synthesis of Novel 1,2,3-Triazolyl-pyrazoline Hybrids
Letters in Organic Chemistry Pharmacological Treatment of Hypoxic-Ischemic Reperfusion Injury of the Newborn Brain in the Clinical Setting: What are the Possibilities in the Near Future?
Current Pediatric Reviews Aporphines and Parkinson’s Disease: Medical Tools for the Future
Current Topics in Medicinal Chemistry Translational Pharmacology in Aging Men with Benign Prostatic Hyperplasia: Molecular and Clinical Approaches to Alpha1-Adrenoceptors
Current Aging Science Possible Therapies of Septic Shock: Based on Animal Studies and Clinical Trials
Current Pharmaceutical Design Cell Cycle Inhibition in Malignant Lymphoma: Disease Control by Attacking the Cellular Proliferation Machinery
Current Drug Targets The Use of Iontophoresis in the Administration of Nicotine and New Non-Nicotine Drugs through the Skin for Smoking Cessation
Current Drug Discovery Technologies Diagnosis and Treatment of Paraneoplastic Neurological Syndromes
Current Clinical Pharmacology Biologicals Dramatic Advances in the Treatment of Psoriasis
Current Pharmaceutical Design Pathogenetic Pathways of Cardiorenal Syndrome and their Possible Therapeutic Implications
Current Pharmaceutical Design Fenoldopam in Cardiovascular Surgery: A Review
Vascular Disease Prevention (Discontinued)